UY26615A1 - Inhibidor de la glucogeno fosforilasa. - Google Patents

Inhibidor de la glucogeno fosforilasa.

Info

Publication number
UY26615A1
UY26615A1 UY26615A UY26615A UY26615A1 UY 26615 A1 UY26615 A1 UY 26615A1 UY 26615 A UY26615 A UY 26615A UY 26615 A UY26615 A UY 26615A UY 26615 A1 UY26615 A1 UY 26615A1
Authority
UY
Uruguay
Prior art keywords
phosphorylase inhibitor
compositions
glucogen
glucogen phosphorylase
inhibitor
Prior art date
Application number
UY26615A
Other languages
English (en)
Inventor
Walter C Babcock
Dwayne Friesen
Douglas LORENZ
Chris Macri
James Alan NIGHTINGALE
Ravi Shanker
Bruno Caspar Hancock
Marshall D Crew
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of UY26615A1 publication Critical patent/UY26615A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Se describen composiciones farmacéuticas de un inhibidor de la glucógeno fosforilasa poco soluble y particularmente eficaz, así como procedimientos para fabricar tales composiciones y formas de dosificación a partir de tales composiciones.
UY26615A 2000-03-16 2001-03-14 Inhibidor de la glucogeno fosforilasa. UY26615A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19012500P 2000-03-16 2000-03-16

Publications (1)

Publication Number Publication Date
UY26615A1 true UY26615A1 (es) 2001-10-25

Family

ID=22700102

Family Applications (1)

Application Number Title Priority Date Filing Date
UY26615A UY26615A1 (es) 2000-03-16 2001-03-14 Inhibidor de la glucogeno fosforilasa.

Country Status (16)

Country Link
US (2) US20010053791A1 (es)
EP (1) EP1263433A2 (es)
JP (2) JP2003526666A (es)
AR (2) AR028253A1 (es)
AU (1) AU2001240978A1 (es)
CA (1) CA2403233A1 (es)
CO (1) CO5271644A1 (es)
GT (1) GT200100039A (es)
MX (1) MXPA02009098A (es)
PA (1) PA8513701A1 (es)
PE (1) PE20011268A1 (es)
SV (1) SV2002000342A (es)
TN (1) TNSN01041A1 (es)
TW (1) TW200304377A (es)
UY (1) UY26615A1 (es)
WO (1) WO2001068092A2 (es)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO5271699A1 (es) * 2000-01-24 2003-04-30 Pfizer Prod Inc Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
US20030086972A1 (en) * 2000-08-09 2003-05-08 Appel Leah E. Hydrogel-driven drug dosage form
EP1269994A3 (en) 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
CN1523979A (zh) * 2001-06-22 2004-08-25 �Ʒ� 非晶形药物吸附物的药物组合物
ES2333645T3 (es) * 2001-06-22 2010-02-25 Bend Research, Inc. Composiciones farmaceuticas de dispersiones de medicamentos y polimeros neutros.
BR0211028A (pt) * 2001-06-22 2004-06-15 Pfizer Prod Inc Solução aquosa, método para formação de associações de fármaco e polìmero, composições farmacêuticas, método para formação de uma composição farmacêutica e produto
US20040253310A1 (en) 2001-09-21 2004-12-16 Gina Fischer Morphine polymer release system
US20040234602A1 (en) * 2001-09-21 2004-11-25 Gina Fischer Polymer release system
GB0126716D0 (en) * 2001-11-07 2002-01-02 Advanced Phytonics Ltd Method for the production of particles
NZ534471A (en) * 2002-01-16 2005-08-26 Kowa Co Medicinal composition containing 2,2-dichloro-12-(4-chlorophenyl)dodecanoic acid
WO2003063822A2 (en) 2002-02-01 2003-08-07 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
RU2288703C2 (ru) * 2002-02-01 2006-12-10 Пфайзер Продактс Инк. Способ создания однородных высушенных распылением твердых аморфных лекарственных дисперсных систем с использованием распыляющих напорных форсунок (варианты) и продукт
EP1920766B1 (en) * 2002-02-01 2017-08-23 Bend Research, Inc Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
BR0307344A (pt) * 2002-02-01 2004-12-14 Pfizer Prod Inc Composições farmacêuticas de dispersões amorfas de fármacos e materiais formadores de microfase lipofìlica
WO2003063831A2 (en) * 2002-02-01 2003-08-07 Pfizer Products Inc. Immediate release dosage forms containing solid drug dispersions
GB0203421D0 (en) * 2002-02-13 2002-04-03 Alizyme Therapeutics Ltd Composition
GB0205166D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205170D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205176D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205162D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205165D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
DE10215908B4 (de) * 2002-04-11 2005-08-18 Aventis Pharma Deutschland Gmbh Acyl-3-carboxyphenyl-harnstoffderivate und deren Verwendung als Arzneimittel
DE10215907A1 (de) * 2002-04-11 2003-11-06 Aventis Pharma Gmbh Acyl-4-carboxyphenyl-harnstoffderivate, Verfahren zu deren Herstellung und deren Verwendung
DE10225635C1 (de) * 2002-06-07 2003-12-24 Aventis Pharma Gmbh N-Benzoylureido-Zimtsäurederivate, Verfahren zu deren Herstellung und deren Verwendung
JP4374428B2 (ja) * 2002-07-11 2009-12-02 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 尿素置換されたおよびウレタン置換されたアシル尿素、それらの製造方法および医薬としてのそれらの使用方法
EP1530457B1 (en) 2002-08-12 2009-09-09 Bend Research, Inc. Pharmaceutical compositions of drugs in semi-ordered form and polymers
EP2301526B1 (en) 2003-03-26 2016-03-23 Egalet Ltd. Morphine controlled release system
FR2857591B1 (fr) * 2003-07-17 2007-11-02 Ethypharm Sa Particules comprenant un principe actif sous forme de co-precipite
EP1653927B1 (en) * 2003-08-04 2012-01-11 Bend Research, Inc. Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials
CL2004001884A1 (es) 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
KR20080083071A (ko) * 2003-08-08 2008-09-12 아지노모토 가부시키가이샤 나테글리니드 함유 제제
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
JP2007517016A (ja) * 2003-12-31 2007-06-28 ファイザー・プロダクツ・インク 低溶解性薬剤及びポロキサマーの固体組成物
US20110027357A1 (en) * 2004-02-18 2011-02-03 Isaac Gilinski Compositions and methods for timed release of water-soluble nutritional supplements
US8158138B1 (en) * 2004-05-20 2012-04-17 Fougera Pharmaceuticals, Inc. Urea compositions and their methods of manufacture
DE602005010074D1 (de) * 2004-05-28 2008-11-13 Pfizer Prod Inc Pharmazeutische zusammensetzungen mit verbesserter leistung enthaltend ein hpmca polymer
BRPI0511900A (pt) * 2004-06-08 2008-01-22 Vertex Pharma composições farmacêuticas
WO2006059163A1 (en) * 2004-12-02 2006-06-08 Prosidion Limited Treatment of diabetes with glycogen phosphorylase inhibitors
US9265731B2 (en) * 2005-01-28 2016-02-23 Bend Research, Inc. Drying of drug-containing particles
EP1844078B1 (en) * 2005-02-03 2016-09-28 Bend Research, Inc Pharmaceutical compositions with enhanced performance
AU2006228947A1 (en) * 2005-03-30 2006-10-05 Mylan Pharmaceuticals Ulc Combined-step process for pharmaceutical compositions
EP1895989A2 (en) * 2005-06-03 2008-03-12 Egalet A/S A solid pharmaceutical composition with a first fraction of a dispersion medium and a second fraction of a matrix, the latter being at least partially first exposed to gastrointestinal fluids
DE102005026755A1 (de) * 2005-06-09 2006-12-14 Basf Ag Herstellung von festen Lösungen schwerlöslicher Wirkstoffe durch Kurzzeitüberhitzung und schnelle Trocknung
EP2502621A1 (en) 2005-06-27 2012-09-26 Valeant International (Barbados) SRL Crystalline forms of bupropion HBr
JP2009514884A (ja) * 2005-11-04 2009-04-09 イーストマン ケミカル カンパニー 難溶性医薬活性剤の投与のためのカルボキシアルキルセルロースエステル
PL1993360T3 (pl) 2005-12-28 2017-08-31 Vertex Pharmaceuticals Incorporated Stałe postacie n-[2,4-bis(1,1-dimetyloetylo)-5-hydroksyfenylo]-1,4- dihydro-4-oksochinolino-3-karboksyamidu
US20070218012A1 (en) 2006-03-20 2007-09-20 Bittorf Kevin J Pharmaceutical Compositions
JP2009530415A (ja) * 2006-03-20 2009-08-27 バーテックス ファーマシューティカルズ インコーポレイテッド 医薬組成物
EP2090298A4 (en) * 2006-11-13 2014-02-26 Kyorin Seiyaku Kk METHOD FOR PRODUCING A TABLET WITH DELAYED RELEASE
PE20081506A1 (es) * 2006-12-12 2008-12-09 Infinity Discovery Inc Formulaciones de ansamicina
MX2009006806A (es) * 2006-12-22 2009-08-27 Vertex Pharma Secado por rocio fluidizado.
EP1938804A1 (en) * 2006-12-22 2008-07-02 Novartis AG Pharmaceutical formulation comprising neurokinin antagonist
NZ577560A (en) * 2007-01-16 2012-01-12 Egalet Ltd Use of i) a polyglycol and ii) an active drug substance for the preparation of a pharmaceutical composition for i) mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse
NZ580972A (en) 2007-06-04 2012-02-24 Egalet Ltd Controlled release pharmaceutical compositions for prolonged effect
US20090004281A1 (en) * 2007-06-26 2009-01-01 Biovail Laboratories International S.R.L. Multiparticulate osmotic delivery system
EP4008314A3 (en) * 2007-08-21 2022-11-09 Board of Regents, The University of Texas System Thermo-kinetic mixing for pharmaceutical applications
US8518381B2 (en) 2008-03-28 2013-08-27 The Procter & Gamble Company Processes of making oral compositions containing gel networks
WO2009129300A2 (en) * 2008-04-15 2009-10-22 Schering Corporation High density compositions containing posaconazole and formulations comprising the same
AU2009236290A1 (en) * 2008-04-15 2009-10-22 Merck Sharp & Dohme Corp. Oral pharmaceutical compositions in a solid dispersion comprising preferably posaconazole and HPMCAS
DE102008022520A1 (de) * 2008-05-07 2009-11-12 Bayer Animal Health Gmbh Feste Arzneimittelformulierung mit verzögerter Freisetzung
AU2010211220B2 (en) 2009-02-06 2013-08-01 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
CA2766179A1 (en) 2009-06-24 2010-12-29 Egalet Ltd. Controlled release formulations
JP5757681B2 (ja) * 2009-08-12 2015-07-29 富士フイルム株式会社 セルロース誘導体、樹脂組成物、成形体及びその製造方法並びに電気電子機器用筐体
TWI461213B (zh) * 2009-11-05 2014-11-21 Fmc Corp 作為藥物賦形劑之微晶纖維素及磷酸鈣之組合物
EP2389934A1 (en) * 2010-05-25 2011-11-30 Sanovel Ilac Sanayi ve Ticaret A.S. Controlled-Release Tablet Formulations of Pregabalin
AU2011332031B2 (en) * 2010-11-24 2017-01-12 Melinta Subsidiary Corp. Pharmaceutical compositions
UY33937A (es) 2011-03-07 2012-09-28 Boehringer Ingelheim Int Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
US9555001B2 (en) * 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
WO2013169523A1 (en) * 2012-05-07 2013-11-14 Bpsi Holdings, Llc. Solubility enhanced compositions
US8313774B1 (en) 2012-06-26 2012-11-20 Magnifica Inc. Oral solid composition
CA2877183A1 (en) 2012-07-06 2014-01-09 Egalet Ltd. Abuse deterrent pharmaceutical compositions for controlled release
WO2014042945A1 (en) * 2012-09-11 2014-03-20 Bend Research, Inc. Methods for making pharmaceutical solid dosage forms of spray-dried dispersions
EP2964243B1 (en) 2013-03-06 2022-11-23 Capsugel Belgium NV Curcumin solid lipid particles and methods for their preparation and use
EP3102188A4 (en) * 2014-02-05 2017-07-12 Merck Sharp & Dohme Corp. Novel disintegration systems for pharmaceutical dosage forms
EP3209960A1 (en) * 2014-10-23 2017-08-30 Bend Research, Inc. Spray nozzle and process for making nanoparticles
PT3212169T (pt) 2014-10-31 2021-05-06 Bend Res Inc Processo para formar domínios ativos dispersos numa matriz
US11324699B2 (en) 2014-12-04 2022-05-10 Capsugel Belgium Nv Lipid multiparticulate formulations
WO2016162229A1 (en) 2015-04-10 2016-10-13 Capsugel Belgium N.V. Abiraterone acetate lipid formulations
CA3050696A1 (en) * 2017-01-20 2018-07-26 Constellation Pharmaceuticals, Inc. Solid dispersions of (r)-n-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1h-indole-3-carboxamide
CA3153332A1 (en) 2019-10-16 2021-04-22 Aouatef Bellamine Method and composition for increasing muscle protein synthesis
WO2021119271A1 (en) 2019-12-10 2021-06-17 Capsugel Belgium Nv Particles containing a lipid matrix core and active ingredient
EP4262805A1 (en) * 2020-12-16 2023-10-25 Merck Sharp & Dohme LLC Mini-tablet dosage form of a viral terminase inhibitor and uses thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US31547A (en) * 1861-02-26 Improvement in polishing iron bars and rods
US27614A (en) * 1860-03-27 Improvement in cultivators
US3146A (en) * 1843-06-24 Improvement in friction-matches
ES2061623T3 (es) 1987-03-02 1994-12-16 Brocades Pharma Bv Procedimiento para la obtencion de una composicion farmaceutica y un granulado farmaceutico.
US4999200A (en) 1987-12-09 1991-03-12 Marion Laboratories Psyllium tablet composition, method of manufacture and method of use
ES2060737T3 (es) 1988-02-25 1994-12-01 Yamanouchi Europ Bv Procedimiento de preparacion de un granulado farmaceutico.
JP3155028B2 (ja) 1991-06-10 2001-04-09 大川原化工機株式会社 噴霧乾燥造粒装置
US5464632C1 (en) 1991-07-22 2001-02-20 Prographarm Lab Rapidly disintegratable multiparticular tablet
DE4220782A1 (de) 1992-06-25 1994-01-05 Basf Ag Verfahren zur Herstellung von festen pharmazeutischen Retardformen
GB9421836D0 (en) 1994-10-28 1994-12-14 Scherer Corp R P Process for preparing solid pharmaceutical dosage forms of hydrophobic substances
GB9511220D0 (en) 1995-06-02 1995-07-26 Glaxo Group Ltd Solid dispersions
WO1997004782A1 (fr) * 1995-07-26 1997-02-13 Kyowa Hakko Kogyo Co., Ltd. Dispersion solide ou preparation a dispersion solide de derives xanthine
US5837292A (en) 1996-07-03 1998-11-17 Yamanouchi Europe B.V. Granulate for the preparation of fast-disintegrating and fast-dissolving compositions containing a high amount of drug
JP3585654B2 (ja) 1996-07-11 2004-11-04 株式会社パウダリングジャパン ２段乾燥式スプレードライヤー装置
CN1222317C (zh) 1996-07-12 2005-10-12 第一制药株式会社 可迅速崩解的压模物质及其生产方法
DE19637082A1 (de) 1996-09-12 1998-03-19 Boehringer Mannheim Gmbh Schnellzerfallende Pellets
US5952322A (en) * 1996-12-05 1999-09-14 Pfizer Inc. Method of reducing tissue damage associated with non-cardiac ischemia using glycogen phosphorylase inhibitors
TW486370B (en) 1996-12-25 2002-05-11 Yamanouchi Pharma Co Ltd Rapidly disintegrable pharmaceutical composition
US5976577A (en) 1997-07-11 1999-11-02 Rp Scherer Corporation Process for preparing fast dispersing solid oral dosage form
PT901786E (pt) * 1997-08-11 2007-08-07 Pfizer Prod Inc Disperções farmacêuticas sólidas com biodisponibilidade melhorada
US5955107A (en) 1997-12-12 1999-09-21 Fmc Corporation Pharmaceutical suspension tablet compositions
JP2000072676A (ja) 1998-09-01 2000-03-07 Taiho Yakuhin Kogyo Kk 吸収を改善した医薬組成物
ATE400252T1 (de) 1999-02-10 2008-07-15 Pfizer Prod Inc Pharmazeutische feste dispersionen
DE60039802D1 (de) * 1999-02-10 2008-09-25 Pfizer Prod Inc Vorrichtung mit matrixgesteuerter Wirkstofffreisetzung
ATE433318T1 (de) 1999-02-10 2009-06-15 Pfizer Prod Inc Osmotisches system zur verabreichung von wirkstoffen, die feste amorphe dispersionen enthalten
US6296149B1 (en) 1999-04-16 2001-10-02 Depuy Orthopaedics, Inc. Monomer delivery device for bone cement delivery system
US6223455B1 (en) 1999-05-03 2001-05-01 Acusphere, Inc. Spray drying apparatus and methods of use
CN1402629A (zh) * 1999-12-23 2003-03-12 辉瑞产品公司 提供提高的药物浓度的药物组合物
BR0016708A (pt) 1999-12-23 2002-10-08 Pfizer Prod Inc Forma de dosagem de droga baseada em hidrogel
US6316029B1 (en) 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form

Also Published As

Publication number Publication date
EP1263433A2 (en) 2002-12-11
MXPA02009098A (es) 2003-03-12
CA2403233A1 (en) 2001-09-20
CO5271644A1 (es) 2003-04-30
SV2002000342A (es) 2002-07-16
TW200304377A (en) 2003-10-01
PE20011268A1 (es) 2001-12-12
GT200100039A (es) 2001-12-31
JP2003526666A (ja) 2003-09-09
US20030185891A1 (en) 2003-10-02
AR040281A2 (es) 2005-03-23
WO2001068092A2 (en) 2001-09-20
AU2001240978A1 (en) 2001-09-24
TNSN01041A1 (fr) 2005-11-10
JP2007182449A (ja) 2007-07-19
US20010053791A1 (en) 2001-12-20
US7235260B2 (en) 2007-06-26
PA8513701A1 (es) 2002-10-24
WO2001068092A3 (en) 2002-03-21
AR028253A1 (es) 2003-04-30

Similar Documents

Publication Publication Date Title
UY26615A1 (es) Inhibidor de la glucogeno fosforilasa.
HN2001000244A (es) Inhibidores de espiropirimidin - 2, 4, 6 - triona metaloproteinasas.
NO20026255L (no) Polymere micellesammensetninger
PL406680A1 (pl) Inhibitory kinaz tyrozynowych
UA91002C2 (ru) 7-фенилалкилзамещенные 2-хинолиноны и 2-хиноксалиноны как ингибиторы поле(адф-рибоза)полимеразы
UY27571A1 (es) 2-tio-3, 5-diciano-4-fenil-6-aminopiridinas sustituidas y su uso
AU3652102A (en) Compounds and their uses
SE0101675D0 (sv) Novel composition
DK1299348T3 (da) Forbindelser og sammensætninger til levering af aktive midler
BR0212921A (pt) Composição farmacêutica com base em fondant
UY27346A1 (es) Composiciones farmaccuticas que contienen conjuntos de polemero y frrmaco.
NO20055130L (no) Aminocykloheksyleter-forbindelser og deres anvendelse
BR0116452A (pt) Composto, composição farmacêutica, uso de um composto
BR0113286B1 (pt) pirazàis substituÍdos e composiÇço farmacÊutica compreendendo os mesmos.
SE0001899D0 (sv) New compounds
ECSP034568A (es) Inhibidores de metaloproteinasa del tipo pirimidin 2,4,6-triona
EA200701065A1 (ru) Инъецируемые составы, содержащие нанодисперсный оланзапин
PL378107A1 (pl) 1,2,4-triazyny hamujące HIV
HUP0401811A2 (hu) Javított vízoldékonyságú gyógyszerkészítmény és eljárás az előállítására
PA8599701A1 (es) Formas de dosificacion y procedimientos de tratamiento que usan inhibidores del vegfr
DE60219005D1 (de) Feste pharmazeutische formulierung enthaltend modafinil
UY28519A1 (es) Derivados de quinazolina
MXPA03010766A (es) Nuevos compuestos y composiciones como inhibicores de las catepsinas.
NO20054346L (no) Sammensetninger og fremgangsmater for forebygging og behandling av endotoksinrelaterte sykdommer og tilstander
TW200509794A (en) Novel anthelmintic and insecticidal compositions

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20130626